Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

the 31 patients with stable disease or better, one

patient had a complete response and four patients had partial

responses (two unconfirmed).

-- SNS-595 has been generally well tolerated in this trial, with a low

rate of febrile neutropenia or other Grade 3/4 adverse events and

manageable Grade 1/2 nausea or vomiting. Based on the drug's

observed safety profile and indications of clinical activity,

Sunesis amended the protocol to explore a higher dose of SNS-595 in

this trial. Enrollment has begun at a dose of 60 mg/m2 over twenty-

eight days, and Sunesis anticipates enrolling approximately 30

patients at this dose in the third quarter of this year.

-- Data from this trial has been accepted for presentation at the 44th

ASCO Annual Meeting.

-- Sunesis updated the results from the company's Phase 1 clinical trial

of single-agent SNS-595 in patients with relapsed or refractory acute

leukemias, which had previously been reported at the 49th Annual

Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia

in December 2007. Since the ASH presentation, an additional patient in

this trial has achieved a complete remission.

-- Twelve of 30 patients (43 percent) who received doses of SNS-595 of

50 mg/m2 or greater on a weekly dose schedule have now achieved bone

marrow blast reductions to less than five percent, and five of these

12 patients achieved either complete remission, complete remission

without platelet recovery or complete remission with incomplete

recovery of normal hematopoietic blood elements.

-- SNS-595 was generally well tolerated in this trial, with a

dose-limiting toxicity of reversible Grade 3/4 oral mucositis.

-- Based on these promising results, Sunesis
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
(Date:11/21/2014)...   TRU-D SmartUVC LLC and its UK partners, ... disinfection robot, TRU-D SmartUVC, at FIS 2014 in ... 26 at Stand 23. The conference, hosted by ... largest infection-related event of its kind and brings ... the leading events of its type throughout the world. This ...
(Date:11/21/2014)... Author Matthew J. Pallamary’s second short story ... published as a tribute to his mentor Ray ... Story” category of the 2014 USA Best Book ... USA Book News, said this year’s contest yielded over ... & Schuster, Penguin, John Wiley & Sons, Houghton Mifflin ...
Breaking Biology Technology:Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... , NEW YORK, Dec. 2 ... is available in its catalogue: , Neurostimulation - ... , The world neurostimulation market stands enthused by ... rise in age-related diseases such as, Parkinson,s, and Alzheimer,s ...
... , NEW YORK, Dec. 2 Reportlinker.com ... in its catalogue: , Drug Discovery Technologies - ... , http://www.reportlinker.com/p0164246/Drug-Discovery-Technologies---A-Global-Update-of-Market-Trends--Opportunities.html , Drug discovery has become ... business strategy. There are a number of new technologies ...
... , COPENHAGEN, Dec. 2 The world,s first ... breakthrough alternative to replace a petrochemically produced ingredient in the ... in Copenhagen, Denmark, this week. One tire will be on ... the Copenhagen International Airport throughout December 21, while the other ...
Cached Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... is pleased to announce the promotion of Yaniv ... of Digital Forensics. In Schiff,s new role as Director, ... team of digital forensics examiners and provide leadership within ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 Schiff ...
(Date:11/7/2014)... CORAL SPRINGS, Florida , November 6, 2014 ... improved secure authentication for better mobile security revolutionizing online transactions. ... NXTD ), Alibaba Holdings Ltd. (NYSE: BABA ), ... MSFT ), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: NXTD and NXTDW), a biometric authentication ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... (June 12, 2013) Seeking to improve the lives ... the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children,s ... in Milwaukee and others are preparing to launch Phase II ... for reducing the disorder,s severest symptoms. Sickle cell anemia ...
... Geskin, PhD, of Florham Park, an expert in water jet ... than 25 years. Sharing the patent with him is Krzysztof ... engineer for Marotta Controls, Montville. US Patent Number 8,459,078 ... a method for using propellant driven water. It teaches ...
... cleaner than fossil fuels, but a Dartmouth College-led study ... stored in deep forest soils. The results appear in ... Global atmospheric studies often don,t consider carbon ... to be stable and unaffected by timber harvesting. But ...
Cached Biology News:New sickle cell anemia therapy advances to Phase II clinical trials 2New sickle cell anemia therapy advances to Phase II clinical trials 3New sickle cell anemia therapy advances to Phase II clinical trials 4Patent awarded today to NJIT for novel use of water jets to create high tensile strength alloy parts 2Wood not so green a biofuel 2
... DNA preparations are prepared from customers ... 1mg to multi-gram scales. Small-scale ... preparations are made according to customer ... according to customer needs, and glycerol ...
... are polypeptide hormones which belong to ... The TGF- superfamily is a large ... control many aspects of development, reproductive ... members incude TGF-s, bone morphogenetic proteins, ...
... GST•Tag™ Antibody Plate is a 96-well ... Antibody. This antibody (mouse IgG 1 ... japonicum glutathione-S-transferase (GST), and binds ... GST•Tag fusion protein in which the ...
... AAIPharmas Routine Testing Laboratory (RTL) can ... over 25 years. ,,Microbial method development ... to monitor the conditions of your ... for manufactured products,,We offer a full ...
Biology Products: